Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 6/20 | 0.63 |
| ▸ | EYA3 | Q99504 | 3/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.54 |
| ▸ | SLC26A4 | O43511 | 3/20 | 0.52 |
| ▸ | THRA | P10827 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.47 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.47 |
| ▸ | APAF1 | O14727 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9760981 | 0.87 | CYP2C9 (0.66) | CYP2C19EYA3CYP2C9KMT2AMEN1 | |
| SCHEMBL28245008 | 0.85 | CYP2C19 (0.79) | CYP2C19EYA3CYP2C9THRATHRB | |
| SCHEMBL9657351 | 0.85 | CYP2C19 (0.63) | CYP2C19EYA3CYP2C9THRATHRB | |
| SCHEMBL20441188 | 0.83 | CYP2C19 (0.61) | CYP2C19EYA3CYP2C9THRATHRB | |
| SCHEMBL4670295 | 0.83 | CYP2C19 (0.61) | CYP2C19EYA3CYP2C9THRATHRB | |
| SCHEMBL1919253 | 0.83 | CYP2C19 (0.61) | CYP2C19EYA3CYP2C9THRATHRB | |
| SCHEMBL23604030 | 0.81 | CYP2C19 (0.59) | CYP2C19EYA3CYP2C9THRATHRB | |
| SCHEMBL18018241 | 0.80 | CYP2C19 (0.61) | CYP2C19EYA3CYP2C9KMT2AMEN1 | |
| SCHEMBL3263341 | 0.80 | CYP2C19 (0.58) | CYP2C19EYA3CYP2C9THRATHRB | |
| SCHEMBL2154703 | 0.79 | KMT2A (0.49) | CYP2C19EYA3CYP2C9SLC26A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115684438-B | Q-TOF-MS-based identification method for adulterated Jiang Hu palm in ginger processed pinellia tuber | 绍兴市食品药品检验研究院 | 2024-07-09 | — | — | CN | claimed |
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | claimed |
| EP-2069332-A2 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | claimed |
| EP-1397341-B1 | 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH CORP (US) | 2008-08-06 | — | — | EP | claimed |
| WO-2008020405-A2 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-02-21 | — | — | WO | claimed |
| EP-1397341-A1 | 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | Wyeth (US) | 2004-03-17 | — | — | EP | claimed |
| US-6589970-B2 | This invention provides novel compounds, pharmaceutical compositions and methods of treating thrombotic disorders in mammals, the compounds having the formula: | WYETH | 2003-07-08 | — | — | US | claimed |
| US-20030045560-A1 | 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH | 2003-03-06 | — | — | US | claimed |
| WO-2003000649-A1 | 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH (US) | 2003-01-03 | — | — | WO | claimed |
| WO-2025111414-A1 | TRPM3-MODULATING BENZOFURAN DERIVATIVES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-05-30 | — | — | WO | disclosed |
| EP-4055014-B1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORP (KR) | 2025-04-30 | — | — | EP | disclosed |
| CN-114867719-B | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2024-06-25 | — | — | CN | disclosed |
| US-11919886-B2 | 4,9-dioxo-4,9-dihydronaphtho[2,3-B]furan-3-carboxamide derivatives and uses thereof for treating proliferative diseases and infectious diseases | ACADEMIA SINICA (TW) | 2024-03-05 | — | — | US | disclosed |
| CN-116761796-A | Aryl derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2023-09-15 | — | — | CN | disclosed |
| EP-1397341-A1 | 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | Wyeth (US) | 2004-03-17 | — | — | EP | disclosed |
| US-6589970-B2 | This invention provides novel compounds, pharmaceutical compositions and methods of treating thrombotic disorders in mammals, the compounds having the formula: | WYETH | 2003-07-08 | — | — | US | disclosed |
| US-20030045560-A1 | 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH | 2003-03-06 | — | — | US | disclosed |
| WO-2003000649-A1 | 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH (US) | 2003-01-03 | — | — | WO | disclosed |
| US-5189041-A | Gastrointestinal and nervous system disorders, cardiovascular disorders, analgesics | SYNTEX (U.S.A.) INC. (US) | 1993-02-23 | — | — | US | disclosed |
| EP-0485962-A2 | New tricyclic compounds | SYNTEX (U.S.A.) INC. (US) | 1992-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | CYP2C19 670/4885EYA3 4010/4885CYP2C9 1183/4885 |
| US-20030045560-A1 | 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | SERPINC1, F11, SERPINE1 | CYP2C19 1188/4885EYA3 3991/4885CYP2C9 1128/4885 |
| US-11919886-B2 | 4,9-dioxo-4,9-dihydronaphtho[2,3-B]furan-3-carboxamide derivatives and uses thereof for treating proliferative diseases and infectious diseases | DHODH, NQO2, PKD1 | CYP2C19 505/4885EYA3 2164/4885CYP2C9 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.